What Cafergot (Caffeine) Treats: Main Uses and Benefits

The combination product is commonly used for symptomatic support during acute episodes of established migraine attacks, including those with or without an aura. This medication may be part of symptomatic management to help address certain vascular headaches and related headache types.

---

This specialized intervention is generally relevant when supportive symptom management is appropriate, particularly in contexts where symptoms associated with acute episodes are intense, and when additional management of discomfort is required. It is used for managing symptoms that become more disruptive during flare-ups of vascular headache. The primary benefit is offering symptomatic relief that helps patients cope more steadily during difficult episodes, which provides supportive relief when symptoms interfere with routine activities. The medication is commonly applied to address the pronounced head pain characteristic of migraine, migraine variants, and so-called histaminic cephalalgia.

---

Quick Fact: Contextual Relevance in Acute Vascular Headaches

This medication is relevant in clinical settings that involve acute or unstable symptom patterns, offering symptomatic support for conditions characterized by periods of heightened symptoms and disruptive manifestations.

Regulatory References

1. NIH DailyMed official information

Eligibility for Cafergot (Ergotamine Tartrate and Caffeine)

The use of Cafergot is strictly defined by regulatory eligibility rules, classifying populations for whom the medicine is contraindicated, restricted, or approved.

Category	Official Regulatory Status
Populations for whom use is allowed	Adults for the acute termination of vascular headaches.
Populations for whom use is contraindicated	Patients with cardiovascular disease (e.g., peripheral vascular disease, coronary artery disease, uncontrolled hypertension), severe hepatic or renal impairment, and sepsis.

---

Category	Official Regulatory Status
Pregnancy and Lactation Status	Contraindicated (FDA Category X in pregnancy; potential for serious adverse reactions in nursing infants).
Age-related Eligibility	Pediatric patients (under 18 years): Safety and efficacy not established; use is not recommended. Older adults (over 65 years): Experience is limited and use is not recommended.
Eligibility-related Restrictions	Contraindicated for co-administration with potent CYP3A4 inhibitors and other vasoconstrictors. Must not be used for chronic daily administration or prophylactic therapy.

Official Interaction Profile for Cafergot (Ergotamine Tartrate / Caffeine)

The official interaction profile for this combination medicine is primarily defined by the clearance of Ergotamine and the risk of compounded vasoconstriction, as documented in regulatory sources (FDA, EMA).

Interaction Severity Classification	Interacting Medicines and Substances	Official Constraints
Contraindicated Combinations	Potent CYP3A4 Inhibitors: Macrolide antibiotics (e.g., Erythromycin, Clarithromycin), HIV protease inhibitors (e.g., Ritonavir), and azole antifungals (e.g., Itraconazole).	Co-administration is prohibited due to the risk of severely elevated Ergotamine serum concentrations, which can lead to vascular ischemia.
Pharmacodynamic Interactions	5-HT1 receptor agonists (Triptans) and other vasoconstrictors.	Co-administration is prohibited due to the potential for additive vasospasm. Separation of administration with Triptans must be 24 hours.
Clinically Significant Substance Notes	Grapefruit Juice and Nicotine (smoking).	Grapefruit juice may increase Ergotamine blood levels due to its CYP3A4 inhibitory effects. Nicotine may also potentiate the drug's vasoconstrictive action.

---

The regulatory profile establishes that the Ergotamine component is critically reliant on the CYP3A4 hepatic enzyme pathway. This metabolic reliance dictates the most severe restrictions, resulting in a large class of contraindicated combinations that significantly raise exposure. Additionally, pharmacodynamic warnings against concurrent vasoconstrictive agents define the secondary set of mandated constraints, including specific timing rules.

How Cafergot (Caffeine) Works: Mechanism of Action

---

Modulating Cranial Vascular Tone and Neurotransmitter Signals

This mechanism centers on the partial agonism of key receptors that govern cranial blood flow. Ergotamine engages 5-HT1 B and alpha1-adrenergic receptors to induce smooth muscle contraction, while Caffeine provides a complementary vasoconstrictive force by antagonizing adenosine receptors. These dual molecular actions modify the diameter of extracerebral vessels and engage pathways that modulate vascular and autonomic signaling.

---

Interrupting the Neurogenic Inflammatory Cascade

Ergotamine targets the trigeminovascular system (TVS) to suppress the release of inflammatory and vasodilatory neuropeptides. By activating presynaptic 5-HT1 D receptors, it reduces the overflow of mediators like CGRP from trigeminal nerve endings. This action initiates or suppresses signaling sequences that lead to downstream effects, altering the signaling characteristics within the targeted sensory pathways. The combination is characterized by a strong mechanistic synergy where the two components influence distinct biological pathways, resulting in coordinated physiological changes in cranial vessel tone and nerve activity.

How to Use Cafergot (Ergotamine Tartrate and Caffeine)

Cafergot is used as an acute, intermittent treatment and is not intended for preventive (prophylactic) or daily chronic administration. To achieve optimal results, treatment is designed to begin at the first sign of the headache attack, or during the early prodromal phase.

---

Administration Routes and Dosing Regimens

Cafergot is provided in two forms, which establish the routes of administration and corresponding dosage protocols for adults:

Form and Route	Starting Dose	Subsequent Dosing & Frequency	Maximum Limits
Oral Tablet	Two tablets (2 mg ergotamine/200 mg caffeine)	May take one additional tablet every 30 minutes if relief is required.	Not to exceed 6 tablets per single attack, or 10 tablets in any 7-day period (10 mg ergotamine).
Rectal Suppository	One suppository (2 mg ergotamine/100 mg caffeine)	May use a second suppository after 1 hour if full relief is needed.	Not to exceed 2 suppositories per single attack, or 5 suppositories in any 7-day period (10 mg ergotamine).

---

Administration Conditions and Constraints

The oral tablets may be taken with or without food. For the rectal suppository form, instructions require removal of the foil wrapper before use, and the suppository must not be cut or broken. The total cumulative dosage of ergotamine from all forms must not exceed 10 mg per week. Furthermore, safety and efficacy have not been established in the pediatric population, and the product is contraindicated in severe hepatic or renal impairment. If a subsequent dose is missed, it should be taken as soon as possible, but double doses are prohibited.

Research evidence / Overview of Studies for Cafergot (Ergotamine/Caffeine)

---

Evidence for Acute Termination of Migraine Attacks

Research exploring the use of the ergotamine and caffeine combination product has largely focused on its role in the acute management of symptoms during established migraine attacks. The research exploring this combination product for acute migraine includes Randomized Controlled Trials (RCTs). These short-term trials were typically designed to compare the effects of the combination against a placebo (an inactive substance) or sometimes against other medicines studied for acute migraine.

Researchers in these studies primarily focused on measurements of headache response, defined as a change in pain severity (from severe headache to mild or no pain) within a short period, such as one or two hours after administration. Studies also monitored the rate at which patients achieved a pain-free state and observed whether the headache returned, known as headache recurrence, during a follow-up period, often extending to 24 or 48 hours. Findings observed in these studies describe patterns of acute symptom change measured over these short time frames. The evidence contributes to understanding symptom patterns in adults experiencing acute migraine.

---

Research Regarding Vascular Headaches and Cluster Headaches

The product was studied for the management of vascular headaches and cluster headaches. Evidence for this more general "vascular headache" category is derived primarily from historical clinical records and regulatory submissions. These studies focused on general outcomes related to the interruption of acute headache episodes but were conducted using less specific diagnostic criteria than are used today.

Regarding cluster headaches, the combination was evaluated in research exploring short-term symptom changes. However, evidence is limited in this area. Findings were often based on smaller, older studies, and there is a limited number of recent, dedicated RCTs for this specific use.

---

Study Design: Focus on Short-Term Outcomes and Research Gaps

The research base is structurally defined by its acute, short-term focus. The follow-up durations were limited in most core trials for acute migraine, with the primary research emphasis placed on measurements within the first few hours. The studies were designed to evaluate how symptoms evolved in the observed populations during the immediate symptomatic phase of an acute episode. The short duration of follow-up means that long-term outcomes are not fully established.

Key limitations also include the age of some fundamental data. Comparative evidence against newer treatments is lacking in some areas, and existing studies indicate differences in the measured speed or extent of change patterns in some populations. Furthermore, data for special groups are limited, meaning outcomes for children or older adults are not fully established.

Key Studies & References

1. Label: ERGOTAMINE TARTRATE AND CAFFEINE tablet, film coated - DailyMed
2. Ergotamine/Caffeine - StatPearls - NCBI Bookshelf
3. Acute Treatment of Cluster Headaches (IHS Review)

Common questions about Cafergot (Caffeine) (FAQ)

---

Q: Can I take this for migraines?

Official drug labels for certain products containing acetaminophen, aspirin, and caffeine specifically list migraine relief as a designated Use. This confirms that regulatory documents recognize its labeled use for this specific type of head pain.

---

Q: Is it safe long-term?

Official product information emphasizes that this medication is intended for temporary use. Regulatory labels provide directions for use, advising users to consult a healthcare professional if pain persists for more than 10 days (for adults) or 5 days (for children). The label also includes a warning against exceeding the maximum daily dose due to the known risk of severe liver damage.

---

Q: Can children 2 years old use it?

Products that are specifically formulated for children, such as oral suspensions and chewable tablets, contain official dosing instructions for children 2 to 3 years old. For children under 2 years of age, official labels recommend consulting a healthcare professional.

---

Q: Is it safe to use while pregnant or breastfeeding?

Regulatory information and official guidance indicate the importance of discussing the use of this medication with a healthcare professional before use during pregnancy or while breastfeeding. Official guidance emphasizes that the final decision regarding use during these periods is determined by the patient and their healthcare provider.

Official Storage and Disposal Requirements

Official regulatory information mandates specific storage conditions based on the product form to ensure stability.

Dosage Form	Temperature Range	Additional Requirements
Tablets	Controlled Room Temperature (20 C to 25 C)	Store in a tightly closed, light-resistant container; protect from moisture and excess heat.
Suppositories	Refrigerated (2 C to 8 C)	Keep from freezing; protect from moisture.

All forms of this medication must be stored out of the sight and reach of children, as explicitly required by regulatory bodies. To maintain the integrity of the active components, tablets must be protected from light. Regarding disposal, unused or expired medication must not be kept. Patients are officially instructed to consult a healthcare professional for guidance on disposal or to utilize a drug take-back program, ensuring compliance with local environmental regulations.